Expertise in
6
conditions

Dr. John A. Stoukides

Geriatrics | Internal Medicine
Prospect Chartercare Rwmc, LLC
700 Smith St, 
North Providence, RI 
 (2567.0 mi)
36 Years of Experience
Expertise in
6
conditions
Prospect Chartercare Rwmc, LLC
700 Smith St, 
North Providence, RI 
 (2567.0 mi)
OverviewInsuranceLocationsClinical Research

Overview

John Stoukides is a Geriatrics specialist and an Internal Medicine provider in North Providence, Rhode Island. Dr. Stoukides has been practicing medicine for over 36 years is highly rated in 6 conditions, according to our data. His top areas of expertise are Alzheimer's Disease, Dementia, Sepsis, Hip Replacement, and Colonoscopy.

His clinical research consists of participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
1989
Specialties
Geriatrics
Internal Medicine
Licenses
Geriatric Medicine in RI
Hospital Affiliations
Roger Williams Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

PROSPECT CHARTERCARE RWMC, LLC
700 Smith St, North Providence, RI 02908

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: LY3372689
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 Mg Tablets in Subjects with Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 Mg Tablets in Subjects with Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 15, 2024
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects with Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects with Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 15, 2024
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2/Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: BIIB092
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)
A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
Enrollment Status: Completed
Publish Date: October 24, 2018
Intervention Type: Drug
View 11 Less Clinical Trials
Similar Doctors
Expertise in
8
conditions
Dr. Douglas P. Kiel
Geriatrics | Internal Medicine
Expertise in
8
conditions
Dr. Douglas P. Kiel
Geriatrics | Internal Medicine

Hebrew Seniorlife Affiliated Medical Group Inc

1200 Centre St, 
Roslindale, MA 
 (35.4 mi)
617-971-5766
Experience:
44+ years
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Douglas Kiel is a Geriatrics specialist and an Internal Medicine provider in Roslindale, Massachusetts. Dr. Kiel has been practicing medicine for over 44 years is highly rated in 8 conditions, according to our data. His top areas of expertise are Osteoporosis, Muscle Atrophy, Postmenopausal Osteoporosis, Fractured Spine, and Hormone Replacement Therapy (HRT). Dr. Kiel is currently accepting new patients.

Expertise in
10
conditions
Dr. Lewis A. Lipsitz
Geriatrics | Internal Medicine
Expertise in
10
conditions
Dr. Lewis A. Lipsitz
Geriatrics | Internal Medicine

Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc

330 Brookline Ave, 
Boston, MA 
 (38.6 mi)
617-754-8612
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Lewis Lipsitz is a Geriatrics specialist and an Internal Medicine provider in Boston, Massachusetts. Dr. Lipsitz is highly rated in 10 conditions, according to our data. His top areas of expertise are Orthostatic Hypotension, Low Blood Pressure, Familial Dysautonomia, Aortic Valve Replacement, and Transcatheter Aortic Valve Replacement (TAVR). Dr. Lipsitz is currently accepting new patients.

Expertise in
5
conditions
Dr. Edward R. Marcantonio
Geriatrics | Internal Medicine
Expertise in
5
conditions
Dr. Edward R. Marcantonio
Geriatrics | Internal Medicine

Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc

330 Brookline Ave, 
Boston, MA 
 (38.6 mi)
617-754-8612
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Edward Marcantonio is a Geriatrics specialist and an Internal Medicine provider in Boston, Massachusetts. Dr. Marcantonio is highly rated in 5 conditions, according to our data. His top areas of expertise are Delirium, Dementia, Alzheimer's Disease, Laminectomy, and Coronary Artery Bypass Graft (CABG). Dr. Marcantonio is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile